文献速递角膜与眼表疾病

局部他克莫司长期治疗腺病毒性角结膜炎后对激素和环孢素抵抗的角膜上皮下浸润

Late-term topical tacrolimus for subepithelial infiltrates resistant to topical steroids and ciclosporin secondary to adenoviral keratoconjunctivitis.
PubMed 文献 · Br J Ophthalmol · 2020-06-20

这项病例系列研究评估了0.03%他克莫司眼膏治疗腺病毒性角结膜炎后至少抵抗2年的角膜上皮下浸润(SEIs)的疗效与安全性。11例患者15眼接受12个月治疗,结果显示从第3个月起最佳矫正视力、CSIS、Fantes评分和Schirmer结果显著改善并持续至12个月。结论提示局部0.03%他克莫司可能对持续至少2年且对糖皮质激素和/或环孢素A治疗抵抗的SEIs有效,且无明显副作用。

要点

  • 0.03%他克莫司眼膏治疗12个月可改善抵抗性SEIs的BCVA、CSIS、Fantes评分和Schirmer结果。
  • 显著改善从第3个月开始,Oxford评分下降需6个月。
  • 1例患者(9.1%)因不能耐受治疗退出。

核心结论

  • 局部0.03%他克莫司可能对至少持续2年且对糖皮质激素和/或环孢素A治疗抵抗的SEIs有效,且无明显副作用。

研究设计与样本

  • 病例系列研究,纳入腺病毒性角结膜炎后SEIs且对局部激素和环孢素A治疗抵抗、在AKC后至少2年才开始治疗的患者,接受0.03%他克莫司眼膏治疗12个月。
  • 共纳入11例患者15眼和16例健康对照16眼,在基线及第1、3、6、12个月随访。

主要发现

  • 研究组从第3个月访视开始BCVA、CSIS、Fantes评分和Schirmer结果显著改善,并持续至12个月治疗结束。
  • Oxford评分下降需要6个月。
  • 1例患者(9.1%)不能耐受治疗。

临床怎么用

  • 对于腺病毒性角结膜炎后持续至少2年且对糖皮质激素和/或环孢素A治疗抵抗的SEIs,可考虑局部0.03%他克莫司眼膏治疗12个月。
  • 治疗期间需随访BCVA、CSIS、Fantes评分、Oxford评分、Schirmer和泪膜破裂时间,并监测眼压和患者主诉以评估安全性。

局限性

  • 本研究为病例系列,样本量小(11例患者15眼),未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Investigation of the efficacy and safety of 12 months of topical tacrolimus 0.03% ointment treatment against the subepithelial infiltrates (SEIs) due to adenoviral keratoconjunctivitis (AKC) resisting at least 2 years was aimed. METHODS: This case series included consecutive patients with SEIs secondary to AKC who were resistant to topical steroid and ciclosporin-A (CSA) treatment and treated with topical 0.03% tacrolimus (Protopic; Fujisawa Healthcare, Teva, Deerfield, Illinois, USA) for 12 months, at least 2 years after AKC. For the evaluation of treatment efficacy, best-corrected visual acuity (BCVA), Fantes score, corneal subepithelial infiltrate score (CSIS), Oxford score, Schirmer and tear breakup time results were evaluated. Intraocular pressure and complaints of the patients were followed for evaluating the safety profile of the treatment. The patients were followed after the baseline visit at the 1st, 3rd, 6th and 12th month. RESULTS: 15 eyes of 11 patients with SEIs and 16 eyes of 16 healthy controls were included in this study. 1 patient (9.1%) could not tolerate the treatment. Significant improvements in BCVA, CSIS, Fantes score and Schirmer results were observed in the study group starting from the 3rd-month visit, and the improvements persisted until the end of 12 months of treatment. CONCLUSION: Topical 0.03% tacrolimus might show efficacy against the SEIs persisting at least 2 years despite corticosteroid and/or CSA treatment without any prominent side effect. While at least a period of 3 months was necessary for a significant improvement in the BCVA, SEIs and Schirmer results, a period of 6 months was necessary for a decrease in Oxford score.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Arici C, Mergen B. Late-term topical tacrolimus for subepithelial infiltrates resistant to topical steroids and ciclosporin secondary to adenoviral keratoconjunctivitis. Br J Ophthalmol. 2020. PMID: 32563992. doi:10.1136/bjophthalmol-2020-316196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。